In a post hoc analysis , the rate of major adverse cardiovascular events ( death from coronary heart disease , nonfatal myocardial infarction , fatal or nonfatal ischemic stroke , or unstable angina requiring hospitalization ) was lower with alirocumab than with placebo ( @ % vs. @ % ; hazard ratio , @ ; @ % confidence interval , @ to @ ; nominal P = @ ) .